%0 Generic %A B., Rack %A E., Zombirt %A E., Trapp %A J., Jückstock %A U., Andergassen %A J., Neugebauer %A B., Kost %A T., Weissenbacher %A U., Jeschke %A C., Schindlbeck %D 2016 %T Supplementary Material for: Comparison of HER2 Expression in Primary Tumor and Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Comparison_of_HER2_Expression_in_Primary_Tumor_and_Disseminated_Tumor_Cells_in_the_Bone_Marrow_of_Breast_Cancer_Patients/5129206 %R 10.6084/m9.figshare.5129206.v1 %2 https://karger.figshare.com/ndownloader/files/8717710 %K Breast cancer %K Circulating tumor cells %K Disseminated tumor cells %K Minimal residual disease %K HER2 %K Bone marrow %K HER2-targeting agent %X Objective: The aim of this study was to measure the human epidermal growth factor receptor 2 (HER2) status of disseminated tumor cells (DTCs) from bone marrow (BM) aspirates and to assess correspondence or discrepancy with the primary tumor. Methods: DTCs were isolated from the BM of 156 breast cancer patients. Cytokeratin-positive DTCs were further analyzed by the chromogenic in situ hybridization method to detect HER2 gene amplification. Results: A significant correlation (p = 0.021) was found between the HER2 status of DTCs and the primary tumors. Sixty-one (68.5%) patients had a corresponding status. However, a shift of phenotype between primary tumor and DTCs was found in the remaining patients. Conclusion: This study showed a significant grade of discordance of the HER2 status between primary tumors and DTCs in the BM of a relevant subgroup of patients. Detection of HER2 amplification on DTCs could therefore help to better stratify patients for a more tailored therapy, since they would benefit from a HER2-targeted therapy. %I Karger Publishers